 Elizabeth Kessler
Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 13 | 2023 | 999 | 2.450 |
Why?
| | Urinary Bladder Neoplasms | 7 | 2022 | 226 | 2.330 |
Why?
| | Carcinoma, Renal Cell | 8 | 2023 | 178 | 2.060 |
Why?
| | Kidney Neoplasms | 10 | 2023 | 347 | 2.020 |
Why?
| | Suicide, Assisted | 6 | 2024 | 25 | 1.800 |
Why?
| | Prostate-Specific Antigen | 3 | 2021 | 160 | 1.330 |
Why?
| | Physicians | 6 | 2024 | 875 | 1.010 |
Why?
| | Oncologists | 2 | 2024 | 35 | 0.950 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 1560 | 0.870 |
Why?
| | Antineoplastic Agents | 9 | 2021 | 2045 | 0.850 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 957 | 0.700 |
Why?
| | Orchiectomy | 3 | 2016 | 67 | 0.650 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.610 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 2 | 2017 | 45 | 0.540 |
Why?
| | Abiraterone Acetate | 1 | 2017 | 14 | 0.540 |
Why?
| | Aged | 24 | 2024 | 22107 | 0.530 |
Why?
| | Plant Extracts | 1 | 2018 | 198 | 0.520 |
Why?
| | Prednisone | 1 | 2017 | 234 | 0.500 |
Why?
| | Capecitabine | 1 | 2015 | 45 | 0.500 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 25 | 0.500 |
Why?
| | Indazoles | 2 | 2014 | 66 | 0.500 |
Why?
| | Frailty | 1 | 2018 | 152 | 0.490 |
Why?
| | Imidazoles | 2 | 2014 | 235 | 0.470 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 55 | 0.460 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 77 | 0.460 |
Why?
| | Deoxycytidine | 1 | 2015 | 164 | 0.460 |
Why?
| | Spinal Neoplasms | 1 | 2014 | 29 | 0.450 |
Why?
| | Quinazolines | 1 | 2015 | 243 | 0.440 |
Why?
| | Anilides | 4 | 2022 | 70 | 0.440 |
Why?
| | Piperidines | 1 | 2015 | 200 | 0.440 |
Why?
| | Testicular Neoplasms | 3 | 2023 | 102 | 0.430 |
Why?
| | Immunotherapy | 1 | 2018 | 596 | 0.430 |
Why?
| | Neoplasm Metastasis | 5 | 2020 | 610 | 0.430 |
Why?
| | Neoplasms | 5 | 2023 | 2454 | 0.420 |
Why?
| | Humans | 50 | 2024 | 129847 | 0.400 |
Why?
| | Canada | 5 | 2023 | 353 | 0.380 |
Why?
| | Geriatric Assessment | 4 | 2021 | 205 | 0.350 |
Why?
| | Pyridines | 4 | 2022 | 478 | 0.350 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 886 | 0.350 |
Why?
| | Aged, 80 and over | 7 | 2021 | 7066 | 0.340 |
Why?
| | Male | 29 | 2024 | 63759 | 0.340 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2015 | 628 | 0.330 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 618 | 0.320 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 70 | 0.320 |
Why?
| | Aging | 2 | 2018 | 1774 | 0.310 |
Why?
| | Caregivers | 2 | 2023 | 809 | 0.300 |
Why?
| | Androgen Antagonists | 3 | 2020 | 79 | 0.290 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 879 | 0.290 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 379 | 0.280 |
Why?
| | Neoplasm Staging | 5 | 2023 | 1282 | 0.280 |
Why?
| | Communication | 2 | 2024 | 847 | 0.270 |
Why?
| | Urothelium | 3 | 2019 | 37 | 0.260 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2019 | 59 | 0.260 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 484 | 0.260 |
Why?
| | Stress, Psychological | 1 | 2014 | 1070 | 0.250 |
Why?
| | Treatment Outcome | 7 | 2019 | 10241 | 0.250 |
Why?
| | Middle Aged | 15 | 2024 | 31177 | 0.230 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5437 | 0.230 |
Why?
| | Penile Neoplasms | 1 | 2023 | 7 | 0.210 |
Why?
| | Subacute Care | 1 | 2024 | 77 | 0.210 |
Why?
| | Terminally Ill | 1 | 2023 | 36 | 0.210 |
Why?
| | Quality of Life | 4 | 2022 | 2695 | 0.200 |
Why?
| | Bone Neoplasms | 2 | 2015 | 229 | 0.200 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 391 | 0.200 |
Why?
| | Skilled Nursing Facilities | 1 | 2024 | 131 | 0.200 |
Why?
| | Female | 17 | 2024 | 68829 | 0.190 |
Why?
| | Adenosine Deaminase | 1 | 2021 | 29 | 0.190 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2344 | 0.180 |
Why?
| | Vasculitis | 1 | 2021 | 65 | 0.180 |
Why?
| | Pilot Projects | 4 | 2023 | 1597 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 181 | 0.180 |
Why?
| | Ureteral Neoplasms | 1 | 2019 | 1 | 0.170 |
Why?
| | Nephroureterectomy | 1 | 2019 | 2 | 0.170 |
Why?
| | Biopsy | 2 | 2021 | 1089 | 0.160 |
Why?
| | Hospice Care | 1 | 2022 | 194 | 0.160 |
Why?
| | Palliative Care | 3 | 2024 | 706 | 0.160 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 542 | 0.160 |
Why?
| | Medical Oncology | 1 | 2021 | 268 | 0.160 |
Why?
| | Colorado | 3 | 2024 | 4410 | 0.150 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 14 | 0.150 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 52 | 0.150 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1106 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 756 | 0.140 |
Why?
| | Patient Discharge | 1 | 2024 | 856 | 0.140 |
Why?
| | Frail Elderly | 1 | 2018 | 120 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2018 | 78 | 0.140 |
Why?
| | Prognosis | 4 | 2023 | 3773 | 0.140 |
Why?
| | Cancer Survivors | 1 | 2022 | 257 | 0.140 |
Why?
| | Checklist | 1 | 2018 | 94 | 0.140 |
Why?
| | Proton Therapy | 1 | 2017 | 12 | 0.140 |
Why?
| | Seminoma | 1 | 2017 | 18 | 0.130 |
Why?
| | Mass Screening | 2 | 2021 | 1192 | 0.130 |
Why?
| | Taxoids | 1 | 2017 | 98 | 0.130 |
Why?
| | Age Factors | 3 | 2018 | 3161 | 0.130 |
Why?
| | Documentation | 1 | 2018 | 185 | 0.130 |
Why?
| | Cisplatin | 1 | 2018 | 299 | 0.130 |
Why?
| | Nutritional Status | 1 | 2018 | 328 | 0.130 |
Why?
| | Adult | 10 | 2024 | 35634 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 304 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2021 | 231 | 0.120 |
Why?
| | Patient Selection | 1 | 2018 | 660 | 0.120 |
Why?
| | Decision Making | 1 | 2022 | 864 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2015 | 98 | 0.110 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 763 | 0.110 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 51 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 160 | 0.110 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.110 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 14 | 0.110 |
Why?
| | Demography | 1 | 2014 | 279 | 0.110 |
Why?
| | Risk Assessment | 2 | 2023 | 3269 | 0.110 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 320 | 0.100 |
Why?
| | Feasibility Studies | 3 | 2023 | 870 | 0.100 |
Why?
| | Energy Metabolism | 1 | 2018 | 875 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 218 | 0.100 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 259 | 0.100 |
Why?
| | Radiosurgery | 1 | 2015 | 321 | 0.100 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 534 | 0.100 |
Why?
| | Bone Diseases | 1 | 2012 | 57 | 0.100 |
Why?
| | Needs Assessment | 1 | 2014 | 357 | 0.100 |
Why?
| | Radiography | 1 | 2014 | 800 | 0.100 |
Why?
| | Health Personnel | 1 | 2018 | 658 | 0.090 |
Why?
| | Drugs, Investigational | 1 | 2011 | 32 | 0.090 |
Why?
| | Urinary Bladder | 1 | 2013 | 176 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1368 | 0.090 |
Why?
| | Sarcoma | 1 | 2013 | 175 | 0.090 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2012 | 204 | 0.090 |
Why?
| | Disease Progression | 1 | 2018 | 2628 | 0.090 |
Why?
| | Pyrimidines | 1 | 2014 | 458 | 0.090 |
Why?
| | Sulfonamides | 1 | 2014 | 497 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1514 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 650 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 417 | 0.080 |
Why?
| | Quality Improvement | 1 | 2018 | 1112 | 0.080 |
Why?
| | B7-H1 Antigen | 2 | 2022 | 198 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 503 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5085 | 0.080 |
Why?
| | Survival Rate | 3 | 2019 | 1872 | 0.080 |
Why?
| | United States | 4 | 2023 | 13913 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 1271 | 0.070 |
Why?
| | Cohort Studies | 1 | 2015 | 5444 | 0.060 |
Why?
| | Nephrectomy | 2 | 2018 | 158 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 9801 | 0.060 |
Why?
| | Conscience | 1 | 2024 | 7 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2023 | 14553 | 0.060 |
Why?
| | Drug Interactions | 2 | 2017 | 397 | 0.050 |
Why?
| | Morals | 1 | 2023 | 70 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 110 | 0.050 |
Why?
| | Telephone | 1 | 2023 | 168 | 0.050 |
Why?
| | SEER Program | 1 | 2023 | 202 | 0.050 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2021 | 20 | 0.050 |
Why?
| | Agammaglobulinemia | 1 | 2021 | 33 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 68 | 0.040 |
Why?
| | Prostate | 1 | 2022 | 173 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2022 | 4896 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2021 | 373 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1005 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 649 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 283 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 256 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 464 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2019 | 647 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1199 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 766 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 43 | 0.030 |
Why?
| | Young Adult | 3 | 2018 | 12467 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 392 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 749 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1125 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 124 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3397 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 129 | 0.030 |
Why?
| | Cytokines | 1 | 2021 | 2022 | 0.030 |
Why?
| | Breeding | 1 | 2013 | 61 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 2013 | 77 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2013 | 143 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 32 | 0.030 |
Why?
| | Keratins | 1 | 2013 | 175 | 0.030 |
Why?
| | Organ Specificity | 1 | 2013 | 295 | 0.030 |
Why?
| | Integrases | 1 | 2013 | 119 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 377 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 193 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2013 | 377 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 117 | 0.020 |
Why?
| | Animals | 4 | 2017 | 35409 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1269 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 3706 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 808 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 605 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1690 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2511 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1829 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6550 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2016 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2135 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1274 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7158 | 0.020 |
Why?
| | Adolescent | 2 | 2017 | 20451 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2018 | 5772 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1161 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 6423 | 0.020 |
Why?
| | Mice | 2 | 2013 | 16983 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3089 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3185 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2378 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4077 | 0.010 |
Why?
|
|
Kessler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|